Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Inclusion Criteria:

• Subject has a clinical diagnosis of stable plaque psoriasis

Exclusion Criteria:

• Subject has spontaneously improving or rapidly deteriorating plaque psoriasis
• Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis
• Subject has used any phototherapy, photo-chemotherapy or systemic psoriasis therapy within 30 days prior to initiation of treatment
• Subject has used systemic corticosteroids or topical, inhaled, intranasal corticosteroids within 30 days and 14 days, respectively, prior to study screening
• Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to initiation of treatment
• Subject has used topical psoriatic therapy including tar, anthralin, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to initiation of treatment
• Subject has used emollients/moisturizers on areas to be treated within one day prior to initiation of treatment
• Subject is currently using lithium or Plaquenil (hydroxychloroquine)
• Subject is currently using a beta-blocking medication (e.g., propranolol) or angiotensin converting enzyme (ACE) inhibitors (e.g., lisinopril) at a dose that has not been stabilized
• Subject is pregnant, nursing or planning a pregnancy during the study period
• Subject is currently enrolled in an investigational drug, biologic or device study
• Subject has received an investigational drug, biologic or an investigational device within 30 days prior to study start
• Subject has been previously enrolled in this study and treated with the test article
• Subject has an irregular sleep schedule or works night shifts